COMMUNIQUÉS West-GlobeNewswire

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08/07/2026
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
08/07/2026
Nantes, le 8 juillet 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
Sienna Announces Second Quarter 2026 Results Release Date and Conference Call
08/07/2026
MARKHAM, Ontario, July 08, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2026 second quarter results after market close on Tuesday, [...]
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
08/07/2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]
Half-Year Report on Liquidity Contract with Invest Securities
08/07/2026
NANTES, France, July 8, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) – Under the liquidity contract entrusted by OSE Immunotherapeutics to Invest Securities, the following resources [...]
SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1)
08/07/2026
Approximately $40 million in cash and more than $15 million in short-term investment assets as of June 30, 2026 1 Estimated net asset value of approximately $60 million and no debt outstanding as of June 30, 2026¹ [...]
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
08/07/2026
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 08 juillet 2026 – GENFIT (Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies [...]
Bilan semestriel du contrat de liquidité avec Invest Securities
08/07/2026
NANTES, France, le 8 juillet 2026, 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) – Au titre du contrat de liquidité confié par OSE Immunotherapeutics à Invest Securities, les moyens suivants [...]
Cannara Biotech Inc. annoncera ses résultats financiers pour le troisième trimestre de l'exercice 2026 le 15 juillet 2026
08/07/2026
MONTRÉAL, 08 juill. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») ( TSX : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0) , producteur verticalement intégré de cannabis [...]
As America Celebrates its 250th Birthday, Becoming Independent Marks 59 Years of Helping People Live on Their Own Terms
08/07/2026
Becoming Independent Named No. 17 on “The NonProfit Times' 2026 Best Nonprofits To Work For” SANTA ROSA, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Becoming Independent , the North Bay's leading nonprofit serving adults [...]
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
08/07/2026
The appointment follows New c elX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101 , providing a clear regulatory pathway toward clinical trials Dr. Ricordi to s upport a dvancement of New c elX's [...]
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
08/07/2026
90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient [...]
Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
08/07/2026
RUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel [...]
Nordic Ranked No. 1 Overall in Black Book’s 2026 Healthcare IT Consulting and Advisory Services Report
08/07/2026
MADISON, Wis., July 08, 2026 (GLOBE NEWSWIRE) -- Nordic ® , a global health and technology consulting company, has been ranked No. 1 overall in Black Book Market Research's 2026 Healthcare IT Consulting & Advisory [...]
Cerene® Cryotherapy Announces Know Your Flow Event Series To Empower Women Through Free Menstrual and Perimenopause Education
08/07/2026
The First Two Events Will Take Place in New York and Charlotte BERKELEY, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Channel Medsystems’ Cerene® Cryotherapy is proud to announce the launch of its Know Your Flow Event [...]
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
08/07/2026
NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report , detailing the company's work on behalf of patients and families living with rare and [...]
Une première mondiale : le protocole de traitement par cellules souches en une seule séance du KFSH de Djeddah établit une nouvelle référence en matière de sécurité des donneurs et d’efficacité thérapeutique
08/07/2026
DJEDDAH, Royaume d’Arabie saoudite, 08 juill. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre de Djeddah a développé et mis en œuvre avec succès le premier protocole de ce type au monde [...]
Tekton Research and Summit Clinical Research Solutions Expand Partnership, Bring MASH Trials to Ohio
08/07/2026
New Carlisle, Ohio site will conduct MASH trials under Ashok Devatha, MD Embedded urgent care operation provides a high-traffic clinical access point, supported by Dr. Devatha’s primary care relationships Collaboration [...]
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
08/07/2026
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated [...]

Pages